BeOne Medicines (BEIGF) Revenue (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Revenue data on file, last reported at $1.5 billion in Q1 2026.

• Revenue for Q1 2026 came in at $1.5 billion, up 35.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 37.44% YoY), and the FY2025 annual result was $5.3 billion, up 40.23% from the prior year.
• Revenue improved to $1.5 billion in Q1 2026 per BEIGF's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Revenue peaked at $1.5 billion in Q1 2026 and troughed at $306.6 million in Q1 2022.
• A 5-year average of $855.4 million and a median of $781.3 million in 2023 frame the typical range for Revenue.
• On a YoY basis, Revenue climbed as much as 127.73% in 2022 and fell as far as 49.39% in 2022.
• A 5-year view of Revenue shows it stood at $380.1 million in 2022, then jumped by 66.91% to $634.4 million in 2023, then jumped by 77.78% to $1.1 billion in 2024, then soared by 32.84% to $1.5 billion in 2025, then climbed by 1.02% to $1.5 billion in 2026.
• Business Quant data shows BEIGF's Revenue at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.